0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
In This Issue of JAMA |

Highlights FREE

JAMA. 2014;311(16):1581-1583. doi:10.1001/jama.2013.279458.
Text Size: A A A
Published online

Edited by Roger N. Rosenberg, MD, and Jeffrey L. Saver, MD

Early thrombolysis with intravenous tissue plasminogen activator is associated with better outcomes in acute ischemic stroke. In a study randomized by week from May 1, 2011, to January 31, 2013, that involved 6182 German adults with suspected stroke, Ebinger and colleagues found that compared with conventional ambulance care, use of an ambulance equipped with a computed tomography scanner, laboratory capability, telemedicine connection, and trained stroke team resulted in decreased time to treatment without an increase in adverse events. In an Editorial, Grotta discusses progress in treatment of ischemic stroke.

Editorial Related Article

In an analysis of registry data from 1030 hospitals (71 169 patients) participating in Target: Stroke, a national acute ischemic stroke care quality improvement program, Fonarow and colleagues assessed door-to-needle times for tissue plasminogen activator (tPA) administration and patient outcomes before and after program initiation. The authors report the Target:Stroke initiative was associated with improved timeliness of tPA administration and lower in-hospital mortality and intracranial hemorrhage.

Editorial Related Article

Acetazolamide is commonly used to treat idiopathic intracranial hypertension (IIH) despite insufficient evidence supporting its use. In a randomized study that enrolled 165 patients with IIH and mild vision loss, Wall and colleagues found that 6 months’ treatment with acetazolamide and a low-sodium weight reduction diet, compared with diet alone, resulted in modest improvement in visual field function. In an Editorial, Horton discusses beneficial effects of acetazolamide in IIH.

Diazepam is approved for the treatment of status epilepticus in children. However, some data suggest lorazepam may be more effective or safer. In a randomized trial involving 273 patients aged 3 months to 18 years who presented to academic pediatric emergency departments with convulsive status epilepticus, Chamberlain and colleagues found that treatment with lorazepam did not result in improved efficacy or safety compared with diazepam.

Whether conservative management is superior to interventional treatment for unruptured brain arteriovenous malformations (bAVM) is not clear. In a prospective cohort study of 204 adults diagnosed with unruptured bAVM and treated with intervention (endovascular embolization, neurosurgical excision, stereotactic radiosurgery) or conservatively (without intervention), Al-Shahi Salman and colleagues found that conservative management was associated with better clinical outcomes through 4 years’ follow-up.

CLINICAL REVIEW & EDUCATION

Parkinson disease is incurable; however, symptomatic therapies can improve patients’ quality of life. In an evidence-based review, Connolly and Lang discuss initial pharmacological treatment of classic motor symptoms; management of medication-related motor complications and other adverse effects; and treatment of selected nonmotor symptoms including depression, cognitive impairment, orthostatic hypotension, and sialorrhea.

A recent article in JAMA Neurology reported an association between higher serum brain-derived neurotropic factor (BDNF) levels and reduced risk of incident dementia. In this From the JAMA Network article, Aisen discusses investigation of BDNF and other biomarkers that may have utility in diagnosis, monitoring, and potential treatment of Alzheimer disease and other dementias.

Deep brain stimulation is an approved treatment for patients with Parkinson disease and severe levodopa-associated motor complications. This Medical Letter article briefly explains the procedure, summarizes adverse effects, and highlights recent data on efficacy—including for patients with early motor complications.

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.